加载中
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
前收盘价
US$3.79
−US$0.06 · -1.56%
盘中时间采用ET。市场数据可能有所延迟。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日内区间
当前US$3.79
52周区间
当前US$3.79
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
23
偏贵
情绪
47
多空交织
风险
59
风险偏高
动量
39
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
日内区间
当前US$3.79
52周区间
当前US$3.79
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CHF） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 497万 CHF | 703.8万 CHF | 1.9亿 CHF | 933万 CHF |
| 销货成本 | 204.86万 CHF | 4750.4万 CHF | 4784.4万 CHF | 5074.9万 CHF | 5571.8万 CHF |
| 毛利 | −204.86万 CHF | −4253.4万 CHF | −4080.6万 CHF | 1.39亿 CHF | −4638.8万 CHF |
| 研究与开发 | 4019.4万 CHF | 4860.4万 CHF | 4878.4万 CHF | 5074.9万 CHF | 5571.8万 CHF |
| 销售、一般及管理费用 | 1487.1万 CHF | 1716.4万 CHF | 1899.5万 CHF | 2182.2万 CHF | 1690.6万 CHF |
| 营业费用 | 5089.42万 CHF | 1868.3万 CHF | 2030.2万 CHF | 7294.3万 CHF | 7274.9万 CHF |
| 利息收入 | 152.2万 CHF | 338.4万 CHF | 427.9万 CHF | 119.57万 CHF | 10.83万 CHF |
| 利息支出 | 1.8万 CHF | 2.5万 CHF | 4.9万 CHF | 64.81万 CHF | 60.81万 CHF |
| 折旧和摊销 | 214.4万 CHF | 236.9万 CHF | 242万 CHF | 238.8万 CHF | 256.5万 CHF |
| 营业利润 | −5812.4万 CHF | −6121.7万 CHF | −6110.8万 CHF | 1.17亿 CHF | −6341.8万 CHF |
| 净利润 | −6165.1万 CHF | −5404.3万 CHF | −6198.4万 CHF | 1.18亿 CHF | −6378.5万 CHF |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.00
上涨空间 454.09%评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
